Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Biohaven Ltd (BHVN)

Biohaven Ltd (BHVN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Biohaven Reports First-in-Human Dosing of Oral PKM2 Modulator, BHV-8100, Targeting Metabolic Restoration and Immunomodulation PR Newswire - Mon Jun 1, 6:30AM CDT

NEW HAVEN, Conn. , June 1, 2026 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization...

BHVN : 11.28 (-0.79%)
Biohaven Reports Positive Clinical Biomarker and Patient Data: First MoDE and TRAP Extracellular Protein Degraders Achieve Deep, Rapid, Selective Lowering of Disease-Driving Antibodies in Graves' Disease and IgA Nephropathy PR Newswire - Wed May 27, 6:30AM CDT

NEW HAVEN, Conn. , May 27, 2026 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) ("Biohaven") a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization...

BHVN : 11.28 (-0.79%)
Biohaven Reports New Clinical Data in Epilepsy with Opakalim, a Selective Kv7.2/7.3 Activator, Highlighting Seizure Control and Markedly Differentiated Tolerability Profile PR Newswire - Tue May 26, 6:30AM CDT

NEW HAVEN, Conn. , May 26, 2026 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing...

BHVN : 11.28 (-0.79%)
Biohaven Reports Recent Business Developments and First Quarter 2026 Financial Results PR Newswire - Mon May 4, 3:02PM CDT

NEW HAVEN, Conn. , May 4, 2026 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization...

BHVN : 11.28 (-0.79%)
Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment PR Newswire - Thu Mar 19, 6:30AM CDT

NEW HAVEN, Conn. , March 19, 2026 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization...

BHVN : 11.28 (-0.79%)
Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results PR Newswire - Mon Mar 2, 3:05PM CST

NEW HAVEN, Conn. , March 2, 2026 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and...

BHVN : 11.28 (-0.79%)
Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference PR Newswire - Mon Jan 12, 10:15AM CST

NEW HAVEN, Conn. , Jan. 12, 2026 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization...

BHVN : 11.28 (-0.79%)
Biohaven to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026 PR Newswire - Wed Jan 7, 6:00AM CST

NEW HAVEN, Conn. , Jan. 7, 2026 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) today announced that Vlad Coric, M.D., Chairman and Chief Executive Officer, will present at the 44th Annual J.P. Morgan...

BHVN : 11.28 (-0.79%)
New York Stock Exchange during sunrise by Deberarr via iStock
S&P Futures Muted in Thin Post-Christmas Trade Barchart - Fri Dec 26, 2025

March S&P 500 E-Mini futures (ESH26) are trending down -0.03% this morning as trading resumed after the Christmas holiday, with activity subdued and volumes expected to remain light ahead of a shortened...

NVDA : 205.19 (+0.16%)
BHVN : 11.28 (-0.79%)
INTC : 124.57 (+6.51%)
NEM : 100.23 (+2.71%)
MU : 981.61 (-1.43%)
LRCX : 366.81 (+1.18%)
NKE : 44.93 (-2.24%)
DVAX : 15.50 (unch)
CPNG : 16.82 (-2.49%)
FCX : 68.41 (+3.12%)
ESH26 : 6,594.63s (-0.22%)
ON : 116.79 (+0.72%)
Biohaven Provides Update From Phase 2 Proof-of-Concept Study with BHV-7000 in Major Depressive Disorder PR Newswire - Wed Dec 24, 2025

NEW HAVEN, Conn. , Dec. 24, 2025 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization...

BHVN : 11.28 (-0.79%)

Barchart Exclusives

Dear Future SK Hynix Stock Investors, Mark Your Calendars for June 22 Barchart - Sun Jun 14, 1:00PM CDT
The SEC is anticipated to approve an application from SK Hynix to list in the U.S. the week of June 22. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.